drugset / Trial / NCT03376516

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

NCT03376516

Phase 3 Completed 11 enrolled Octapharma
NaSingle-groupOpen-labelTreatment

Summary

A prospective, non-controlled, international, multi-centre phase 3 study to investigate the pharmacokinetics, efficacy, safety, and immunogenicity of Wilate in previously treated children with severe haemophilia A

Timeline

Start
2017-11-22
Primary completion
2018-11-03
Completion
2018-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Wilate Protein / enzyme biologic

Indications